

Influence of bisphosphonates or recombinant human parathyroid hormone on *in vitro* sensitivity of acute lymphoblastic leukemia cells to chemotherapy

Demi T.C. de Winter,¹ Jenneke E. van Atteveld,¹ Jessica G.C.A.M. Buijs-Gladiness,¹ Rob Pieters,¹ Sebastian J.C.M.M. Neggers,^{1,2} Jules P.P. Meijerink^{1,3} and Marry M. van den Heuvel-Eibrink¹

¹Princess Máxima Center for Pediatric Oncology, Utrecht; ²Department of Endocrinology, Erasmus Medical Center, Rotterdam and ³Acerta-Pharma (belonging to the AstraZeneca Group), Oss, the Netherlands.

Correspondence:

D.T.C. DE WINTER - d.t.c.dewinter-2@prinsesmaximacentrum.nl

<https://doi.org/10.3324/haematol.2022.281033>

Supplementary Material

Influence of bisphosphonates or recombinant human parathyroid hormone on *in vitro* chemotherapy sensitivity of acute lymphoblastic leukemia cells

Content of Supplementary Appendix

| | |
|--|---|
| Supplementary Table 1 (Table S1). | 2 |
| Supplementary Table 2 (Table S2). | 3 |
| Supplementary Figure 1 (Figure S1). | 4 |

Table S1. Median combination index (CI) values for the effects of the bone-modifying agents (zoledronic acid, pamidronic acid, and recombinant human parathyroid hormone (rhPTH) with a concentration up to five-fold peak plasma concentration) on the chemotherapeutic agent-induced cytotoxicity of vincristine, daunorubicin, dexamethasone, 6-mercaptopurine and PEG-asparaginase.

N = total of evaluable leukemia cell lines. Ranges of CI values: 0.90-1.10 = (near) additive (\pm), 0.30-0.70 = synergism (+++), 0.70-0.85 = moderate synergism (++) , 0.85-0.90 = slight synergism (+), 1.10-1.20 = slight antagonism (-), 1.20-1.45 = moderate antagonism (--), and 1.45-3.30 = antagonism (---).

| | Zoledronic acid (5fold) | | Pamidronic acid (5fold) | | rhPTH (15fold) | |
|-------------------------------|-------------------------|--------|-------------------------|--------|-------------------------|--------|
| | Median (range) | Effect | Median (range) | Effect | Median (range) | Effect |
| Vincristine (n=9) | 1.192 (0.849-2.291) | - | 1.926 (0.625-3.584) | - | 2.719 (0.706-6.294) | --- |
| Daunorubicin (n=9) | 1.074 (1.017-1.312) | \pm | 1.014 (0.983-1.224) | \pm | 1.047 (1.013-1.446) | \pm |
| Dexamethasone (n=4) | 1.153 (1.051-1.535) | - | 1.343 (1.003-1.682) | -- | 0.9610 (0.666-1.022) | \pm |
| 6-Mercaptopurine (n=8) | 1.082 (0.937-1.191) | \pm | 0.9194 (0.804-1.027) | \pm | 0.9764 (0.812-1.054) | \pm |
| PEG-Asparaginase (n=9) | 1.092 (0.784-2.167) | \pm | 1.007 (0.959-1.313) | \pm | 1.039 (0.863-1.384) | \pm |

Table S2. Median combination index (CI) values for the effects of the bone-modifying agents (zoledronic acid and pamidronic acid with an one-, three-, or five-fold psychological peak plasma concentration) on the chemotherapeutic agent-induced cytotoxicity of dexamethasone and prednisone.

N = total of evaluable leukemia cell lines. Ranges of CI values: 0.90-1.10 = (near) additive (\pm), 0.30-0.70 = synergism (+++), 0.70-0.85 = moderate synergism (++) , 0.85-0.90 = slight synergism (+), 1.10-1.20 = slight antagonism (-), 1.20-1.45 = moderate antagonism (--), and 1.45-3.30 = antagonism (---).

| | Zoledronic acid (1fold) | | Zoledronic acid (3fold) | | Zoledronic acid (5fold) | |
|---------------------|-------------------------|--------|-------------------------|--------|-------------------------|--------|
| | Median (range) | Effect | Median (range) | Effect | Median (range) | Effect |
| Dexamethasone (n=4) | 1.057 (0.806-1.221) | \pm | 1.044 (0.877-1.812) | \pm | 1.150 (1.058-1.515) | - |
| Prednisone (n=4) | 1.024 (0.831-1.110) | \pm | 1.061 (0.824-1.239) | \pm | 1.061 (0.949-1.305) | \pm |
| | Pamidronic acid (1fold) | | Pamidronic acid (3fold) | | Pamidronic acid (5fold) | |
| | Median (range) | Effect | Median (range) | Effect | Median (range) | Effect |
| Dexamethasone (n=4) | 0.9202 (0.606-1.082) | \pm | 0.9778 (0.865-2.454) | \pm | 1.336 (1.019-1.961) | -- |
| Prednisone (n=4) | 0.9883 (0.759-1.045) | \pm | 1.020 (0.687-1.100) | \pm | 0.9989 (0.948-1.272) | \pm |

Figure S1. Scatterplots (A-C) visualizing the combination index (CI) values per individual leukemia cell line and the median CI (and range) for all leukemia cell lines combined.

A Scatterplot for the combined treatment of zoledronic acid and vincristine. **B** Scatterplot for the combined treatment of pamidronic acid and vincristine. **C** Scatterplot for the combined treatment of recombinant human parathyroid hormone and vincristine. Each dot on the scatterplot represents the CI value per individual T-ALL or B-precursor cell line. Data are presented as the mean CI of three independent experiments. The median and range for all leukemia cell lines combined is presented in red.

